NCT05775887 is a Phase 1 clinical trial of UQSC2 Vaccine in COVID-19, sponsored by The University of Queensland.

Who is sponsoring NCT05775887?

NCT05775887 is sponsored by The University of Queensland.

What drugs are being tested in NCT05775887?

Interventions in NCT05775887: UQSC2 Vaccine, NVX-CoV2373 vaccine.

Is NCT05775887 still recruiting?

NCT05775887 is currently completed. Last updated 6 March 2024.

Last reviewed 2024-03-06 · How we verify

NCT05775887

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A FIRST IN HUMAN TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF SARS-CoV-2 UQSC2 VACCINE IN HEALTHY ADULTS.

Completed Phase 1 Last updated 6 March 2024

What this trial tests

Phase 1 trial testing UQSC2 Vaccine in COVID-19 in 70 participants. Completed in 16 December 2023.

Timeline

8 May 2023

Primary endpoint
2 December 2023

16 December 2023

Quick facts

Lead sponsor	The University of Queensland
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	prevention
Enrollment	70
Start date	8 May 2023
Primary completion	2 December 2023
Estimated completion	16 December 2023
Sites	1 location across Australia

Drugs / interventions tested

UQSC2 Vaccine — full drug profile →
NVX-CoV2373 vaccine — full drug profile →

Conditions studied

COVID-19 — all drugs for COVID-19 →

Sponsor

The University of Queensland

Who can join

Adults 18 to 50, any sex, with COVID-19. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This will be a single centre, Phase 1, First-In-Human , Randomized, Active-controlled (2- arm) Double-blind, single dose, parallel design study. The study will be conducted in a young healthy adult population aged ≥ 18 - ≤ 50 years. This study will consist of a single cohort of 70 subjects (35 receiving a single dose of UQSC2 vaccine and 35 subjects receiving a single dose of a TGA (Therapeutic Goods Administration) registered SARS-CoV-2 vaccine NVX-CoV2373).

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

A second-generation molecular clamp stabilised bivalent candidate vaccine for protection against diseases caused by respiratory syncytial virus and human metapneumovirus.
Young A, Kolekar S, Mendoza CA, Jaberolansar N, et al · · 2025 · cited 4× · PMID 40674411 · DOI 10.1371/journal.ppat.1013312
Long-term safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2 in adults aged 18-55 years or ≥56 years: 12-month results from a randomised, double-blind, placebo-controlled, phase 1 trial.
Chappell KJ, Mordant FL, Amarilla AA, Modhiran N, et al · · 2023 · cited 3× · PMID 37865043 · DOI 10.1016/j.ebiom.2023.104842
Safety and Immunogenicity of a Severe Acute Respiratory Syndrome Coronavirus 2 Spike Subunit Vaccine Stabilized in the Prefusion Conformation by a Second-Generation Molecular Clamp and Evaluated in Adults Aged 18-55 Years: A Randomized, Double-Blind, Active Comparator, Phase I Tr
Chappell KJ, Mordant FL, Amarilla AA, Modhiran N, et al · · 2026 · PMID 41285172 · DOI 10.1093/infdis/jiaf568

Verify or expand the search:

Other recruiting trials for COVID-19

Currently open trials in the same condition.

NCT07183709 — Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults · Phase 1 · active not recruiting
NCT07300839 — A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age · Phase 3 · active not recruiting
NCT07221162 — A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes · Phase 1 · recruiting
NCT07215520 — Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults · Phase 2 · recruiting
NCT07222384 — A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That A · Phase 3 · active not recruiting

Other The University of Queensland trials

Trials by the same sponsor.

NCT06120673 — REmission in Membranous Nephropathy International Trial (REMIT) · Phase 3 · withdrawn
NCT06642597 — STarting incrEmental Prescription of Peritoneal Dialysis · NA · recruiting
NCT07114354 — Enhancing Utility of Neuropsychological Evaluation for Earlier and Effective Diagnosis of Dementia in Parkinson's Diseas · NA · not yet recruiting
NCT06806709 — Reducing Blood Culture Contamination With the Use of a Needle-less Blood Draw Device (The PIVO Trial) · NA · recruiting
NCT06882239 — SPINEPASS: SPINE Self-management Techniques for Persistent Headache After Concussion: Physical Therapy Targeting Autonom · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05775887 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by The University of Queensland
Last refreshed: 6 March 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05775887.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing